There is an expectation that biosimilars will reap billions of dollars in saving for U.S. consumers by 2020. But adoption could be slowed by a "rebate trap," two Yale medical experts say.
Years ago, teaching hospitals started raising hurdles to pharma reps. A few even barred salespeople at the door. They may have changed prescribing habits, too.
AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint a mixed picture of the drug's safety.
Cancer drug websites load up on numbers about benefits, but tread lightly on side effects, an FDA study found. It’s the latest to flag weaknesses in cancer drug advertising and promotions.